Nanomembrane-based Apheresis as Safe and Effective Therapy for Cytomegalovirus and Epstein-Barr Virus Reactivation

Vjeroslava Slavic; Beti Djurdjic; Danijela  Randjelovic; Gordana Rajovic; Marina Delic

doi:10.3889/oamjms.2021.7534

Authors

Vjeroslava Slavic Cabinet for Apheresis, Institute for Physical medicine, Rehabilitation and Rheumatology, “Dr Simo Milosevic”, Igalo, Montenegro; Centre of Excellence for Biomedical Researches, Institute for Physical medicine, Rehabilitation and Rheumatology, “Dr Simo Milosevic”, Igalo, Montenegro https://orcid.org/0000-0003-2014-3220
Beti Djurdjic Centre of Excellence for Biomedical Researches, Institute for Physical medicine, Rehabilitation and Rheumatology, “Dr Simo Milosevic”, Igalo, Montenegro
Danijela Randjelovic Cabinet for Apheresis, Institute for Physical medicine, Rehabilitation and Rheumatology, “Dr Simo Milosevic”, Igalo, Montenegro; Centre of Excellence for Biomedical Researches, Institute for Physical medicine, Rehabilitation and Rheumatology, “Dr Simo Milosevic”, Igalo, Montenegro
Gordana Rajovic Centre of Excellence for Biomedical Researches, Institute for Physical medicine, Rehabilitation and Rheumatology, “Dr Simo Milosevic”, Igalo, Montenegro
Marina Delic Cabinet for Apheresis, Institute for Physical medicine, Rehabilitation and Rheumatology, “Dr Simo Milosevic”, Igalo, Montenegro; Centre of Excellence for Biomedical Researches, Institute for Physical medicine, Rehabilitation and Rheumatology, “Dr Simo Milosevic”, Igalo, Montenegro

DOI:

https://doi.org/10.3889/oamjms.2021.7534

Keywords:

Apheresis, Marathon runner, Cytomegalovirus and Epstein-Barr virus reactivation

Abstract

BACKGROUND: Heavy training schedules or endurance competitions in marathon are forms of extreme physical stress and lead to immunodepression in runners which could be associated with increased susceptibility to viral reactivation by ubiquitous viral infection such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV). Lately, it was confirmed presence of elevated CMV and EBV loads and the lower antibody titers in competitive athletes. The most common clinical features are fatigue and adynamia accompanied with liver damage, varying from mild and transient elevation of aminotransferases to serious acute hepatitis and liver failure.

CASE REPORT: Bearing in mind that a professional practice of marathon running is hazardous for the liver, therapeutic action is necessary as soon as possible to avoid serious complications and even cessation of professional competition. In our case report of professional female marathon runner, we need to treat CMV and EBV reactivation which caused liver damage, prevented regular trainings, and upcoming competitions. We opted for four sessions of nanomembrane based apheresis performed every other day for removal pathological products resulting from virus reactivation to break through the course of the disease and to prevent complications. After completing the whole procedure control laboratory tests and abdominal ultrasound were in physiological ranges.

CONCLUSION: Hence, nanomembrane based apheresis can be effective and safe treatment of liver damages for elite marathon runners as well as for athletes.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Gandhi MK, Khanna R. Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4(12):725-38. https://doi.org/10.1016/S1473-3099(04)01202-2 PMid:15567122 DOI: https://doi.org/10.1016/S1473-3099(04)01202-2

Maeda A, Sato T, Wakiguchi H. Epidemiology of Epstein-Barr virus (EBV) infection and EBV-associated diseases. Nihon Rinsho. 2006;64(3):609-12. PMid:16615544

Crucian B, Simpson RJ, Mehta S, Stowe R, Chouker A, Hwang SA, et al. Terrestrial stress analogs for spaceflight associated immune system dysregulation. Brain Behav Immun. 2014;39:23-32. https://doi.org/10.1016/j.bbi.2014.01.011 PMid:24462949 DOI: https://doi.org/10.1016/j.bbi.2014.01.011

Mehta SK, Crucian BE, Stowe RP, Simpson RJ, Ott CM, Sams CF, et al. Reactivation of latent viruses is associated with increased plasma cytokines in astronauts. Cytokine. 2013;61(1):205-9. https://doi.org/10.1016/j.cyto.2012.09.019 PMid:23107825 DOI: https://doi.org/10.1016/j.cyto.2012.09.019

Glaser R, Friedman SB, Smyth J, Ander R, Bijur P, Brunell P, et al. The differential impact of training stress and final examination stress on herpesvirus latency at the United States military academy at west point. Brain Behav Immun. 1999;13(3):240-51. https://doi.org/10.1006/brbi.1999.0566 PMid:10469525 DOI: https://doi.org/10.1006/brbi.1999.0566

Sarid O, Anson O, Yaari A, Margalith M. Human cytomegalovirus salivary antibodies as related to stress. Clin Lab. 2002;48(5-6):297-305. PMid:12071580

Walsh NP, Gleeson M, Pyne DB, Nieman DC, Dhabhar FS, Shepard RJ, et al. Position statement. Part two: Maintaining immune health. Exerc Immunol Rev. 2011;17:64-103. PMid:21446353

Gallegos-Orozco JF, Rakela-Brodner J. Hepatitis viruses: Not always what it seems to be. Rev Med Chil. 2010;138(10):1302-11. PMid:21279280 DOI: https://doi.org/10.4067/S0034-98872010001100016

Mendez-Sanchez N, Aguilar-Dominguez C, Chavez-Tapia NC, Urube M. Hepatic manifestations of Epstein-Barr viral infection. Ann Hepatol. 2005;4(3):205-9. PMid:16177662 DOI: https://doi.org/10.1016/S1665-2681(19)32068-X

Gleeson M, Nieman DC, Pedersen BK. Exercise, nutrition and immune function. J Sports Sci. 2004;22(1):115-25. https://doi.org/10.1080/0264041031000140590 PMid:14971437 DOI: https://doi.org/10.1080/0264041031000140590

Armstrong N, Mc Manus AM. The elite young athlete. Med Sport Sci. 2011;56:1-3. https://doi.org/10.1159/isbn.978-3-8055-9551-3 DOI: https://doi.org/10.1159/isbn.978-3-8055-9551-3

Whittaker JL, Woodhouse LJ, Nettel-Aguirre A, Emery CA. Outcomes associated with early post-traumatic osteoarthritis and other negative health consequences 3-10 years following knee joint injury in young sport. Osteoarthritis Cartilage. 2015;23(7):1122-9. https://doi.org/10.1016/j.joca.2015.02.021 PMid:25725392 DOI: https://doi.org/10.1016/j.joca.2015.02.021

Alexandrov AS, Vassileva P, Momchilova A,Tsoncev Z, Kirilova Y, Ivanova R, et al. A new approach using nanomembrane-based therapeutic plasmapheresis for treatment of patients with multiple sclerosis and neuromyelitis optica. Bulgarian Academy of Sci. 2016;69(3):373-84. Available from: https://www.researchgate.net/publication/301753035_A_new_approach_using_nanomembrane-based_therapeutic_plasmapheresis_for_treatment_of_patients_with_multiple_sclerosis_and_neuromyelitis_optica

Voinov VA, Karchevskz KS, Isauliv OV. Plasmapheresis in the treatment of chronic liver diseases. Acta Sci Gastrointest Disord. 2019;2(4):28-38.

Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly- Smith L, Delaney M, et al. Recommendation on the application of therapeutic apheresis in clinical practice-based editorial committee for apheresis: Seventh special edition. Part 1. American society for apheresis (ASFA). J Clin Apher. 2016;31:149-338. DOI: https://doi.org/10.1002/jca.21470

Spence L, Brown WJ, Pyne DB, Nissen MD, Sloots TP, McCormack JG, et al. Incidence, etiology, and symptomatology for upper respiratory illness in elite athletes. Med Sci Sports Exerc. 2007;39(4):577-86. https://doi.org/10.1249/mss.0b013e31802e851a PMid:17414793 DOI: https://doi.org/10.1249/mss.0b013e31802e851a

Hoffmann D, Wolfarth B, Horterer HG, Halle M, Reichhuber C, Nadas K, et al. Elevated Epstein-Barr virus loads and lower antibody titers in competitive athletes. J Med Virol. 2010;82(3):446-51. https://doi.org/10.1002/jmv.21704 PMid:20087932 DOI: https://doi.org/10.1002/jmv.21704

Balfour HH, Dunmire SK, Hogquist KA. Infectious mononucleosis. Clin Transl Immunology. 2015;4(2):e33. https://doi.org/10.1038/cti.2015.1 PMid:25774295 DOI: https://doi.org/10.1038/cti.2015.1

de Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus infection: Problem and solution. World J Virol. 2012;1(1):31-43. https://doi.org/10.5501/wjv.v1.i1.31 PMid:24175209 DOI: https://doi.org/10.5501/wjv.v1.i1.31

Voinov VA. Therapeutic apheresis in metabolic syndrome. Immunol Endocr Metab Agents Med Chem. 2018;18(1):38-54. https://doi.org/10.2174/1871522218666180608114536 PMid:30369968 DOI: https://doi.org/10.2174/1871522218666180608114536

Voinov VA. Plasmapheresis for Critically Ill Patients. Saint-Petersburg:Novosti;2014. p. 13.

Schwartz J, Winters JL, Aqui N, Balogun RA, Connelly-Smith L, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: The sixth special issue. J Clin Apher. 2013;28(3):145-284. https://doi.org/10.1002/jca.21276 PMid:23868759 DOI: https://doi.org/10.1002/jca.21276

Slavic V. Apheresis procedure could prevent sequele of HSV1 encephalitis-case report. Ann Antivir Antiretrovir. 2020;4(1):10-3. https://doi.org/10.17352/aaa.000009 DOI: https://doi.org/10.17352/aaa.000009